Results 161 to 170 of about 827 (180)
Some of the next articles are maybe not open access.
Infectious Disorders - Drug Targets
Background: Sulbactam-durlobactam (SUL-DUR) has been tested in vitro for its ability to gen- erate resistance in clinical isolates of Acinetobacter species. According to prior studies, combining durlobac- tam with sulbactam causes sulbactam-resistant isolates to become more active and revert to susceptibility.
Hemasri Velmurugan +4 more
openaire +2 more sources
Background: Sulbactam-durlobactam (SUL-DUR) has been tested in vitro for its ability to gen- erate resistance in clinical isolates of Acinetobacter species. According to prior studies, combining durlobac- tam with sulbactam causes sulbactam-resistant isolates to become more active and revert to susceptibility.
Hemasri Velmurugan +4 more
openaire +2 more sources
Sulbactam–durlobactam for Acinetobacter pneumonia
The Lancet Infectious Diseases, 2023Ammara Mushtaq, Abhinandan Anand Raman
openaire +1 more source
Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex
The Lancet Infectious Diseases, 2023Giuliano S., Sbrana F., Tascini C.
openaire +3 more sources
Expert Review of Anti-infective Therapy
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a critical priority pathogen posing a substantial threat to our public health due to its virulence and resistance to broad-spectrum antimicrobials. Sulbactam-durlobactam (Xacduro) is a newly approved β-lactam-β-lactamase inhibitor combination agent with potent in vitro and in vivo activity against ...
Yakun, Fu +2 more
openaire +2 more sources
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a critical priority pathogen posing a substantial threat to our public health due to its virulence and resistance to broad-spectrum antimicrobials. Sulbactam-durlobactam (Xacduro) is a newly approved β-lactam-β-lactamase inhibitor combination agent with potent in vitro and in vivo activity against ...
Yakun, Fu +2 more
openaire +2 more sources
Clinical Microbiology and Infection
Carbapenem-resistant Acinetobacter baumannii poses a critical threat, with carbapenem-resistance rate exceeding 70% and limited therapeutic options in China. This multicentre study aimed to evaluate in vitro activity and resistance mechanisms of sulbactam/durlobactam (SUL-DUR), a newly approved β-lactam/β-lactamase inhibitor combination in China ...
Qingye, Xu +6 more
openaire +2 more sources
Carbapenem-resistant Acinetobacter baumannii poses a critical threat, with carbapenem-resistance rate exceeding 70% and limited therapeutic options in China. This multicentre study aimed to evaluate in vitro activity and resistance mechanisms of sulbactam/durlobactam (SUL-DUR), a newly approved β-lactam/β-lactamase inhibitor combination in China ...
Qingye, Xu +6 more
openaire +2 more sources
Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review
Antibiotics, 2022Luigi Principe +2 more
exaly
Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii
Antibiotics, 2023Spyros Pournaras +2 more
exaly